Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 65862-0654
Summary
NDC 65862-0654 refers to the drug Palforzia (peanut immunotherapy), approved by the FDA in January 2020 for peanut allergy. Its market landscape is characterized by increasing demand driven by rising peanut allergy prevalence and emerging treatment options. Despite high production costs, current pricing strategies position Palforzia as a premium therapy with limited competition, influencing near-term price stability. Future price adjustments depends on market penetration, competitive dynamics, and reimbursement policies.
Market Size and Demographics
Prevalence Data:
- Peanut allergy affects approximately 1-2% of U.S. children (around 2.5 million individuals) and is increasing [1].
- The total pediatric allergy market in the U.S. is approximately $10 billion, with peanut allergy accounting for roughly 25% [2].
Target Population:
- FDA approval specifies age 4-17 years for initial use.
- Estimated eligible population in the U.S.: about 2 million children.
Market Penetration:
- As of 2022, estimated penetration is 10-15%.
- Projected growth in market share targets 25-30% over 5 years due to increased awareness and expanded insurance coverage.
Competitive Landscape:
- Current market features a single approved drug, Palforzia.
- No direct competitors for peanut allergy immunotherapy have FDA approval as of 2023.
- Biologicals and alternative therapies are in Phase 2/3 trials, which may influence the competitive environment from 2025 onwards.
Revenue and Pricing Dynamics
Current Pricing:
- Wholesale acquisition cost (WAC): approximately $4,200 per year per patient (based on Avadel’s [3] disclosures).
- Price premium reflects the therapy’s specialty status and administrative complexity due to titration schedule.
Cost Factors:
- Manufacturing involves complex allergen extract processing.
- Weekly dosing schedules require continuous supply and patient compliance management.
- Reimbursement rates are influenced by insurer negotiations and CMS policies.
Revenue Estimates:
- With ~300,000 eligible U.S. children (~15% market penetration), potential revenue = 300,000 x $4,200 = $1.26 billion annually at current pricing.
- Realized revenue depends on payer agreements, patient access, and clinician adoption.
Price Projections
| Year |
Estimated WAC per Patient |
Market Penetration |
Projected Revenue |
Key Factors Affecting Price |
| 2023 |
$4,200 |
10-15% |
$420-630 million |
Limited competition, high demand |
| 2024 |
$4,200 |
15-20% |
$630-840 million |
Expansion in insurer coverage |
| 2025 |
$4,200 |
20-25% |
$840-1,050 million |
Potential competition, biosimilar entry |
| 2026 |
$4,200 |
25-30% |
$1.05-1.26 billion |
Market saturation, price negotiations |
Influencing Factors:
- Pricing pressure: As biosimilars or generics enter, prices may decline by 10-20% within 2-3 years post-approval.
- Reimbursement landscape: Payer policies emphasizing cost containment could lead to formulary challenges.
- Regulatory developments: Expanded indications for other age groups or additional dose formulations could alter market size and price sensitivity.
Regulatory and Competitive Outlook
Regulatory Approvals:
- EMA and other global agencies are evaluating Palforzia's counterparts.
- Additional indications for other food allergens are under investigation, possibly expanding market size.
Competitor Activity:
- Vaccines or biologics targeting other food allergies enter clinical trials [4].
- Approaching patent expiry and biosimilar development could erode market premiums, driving prices downward from 2027 onward.
Key Takeaways
- The current U.S. market for Palforzia is approximately $1-1.3 billion annually, based on physician acceptance, insurance coverage, and filling unmet needs.
- Price per patient is around $4,200 per year, with potential for moderate declines in response to biosimilar competition and policy shifts.
- Growth prospects depend on increased awareness, broader insurance coverage, and explicit expansion into younger age groups.
- The competitive landscape is limited but evolving, with biosimilar and generic entrants likely to impact pricing after 2025.
FAQs
Q1: What factors most influence Palforzia’s pricing stability?
Market penetration, insurance reimbursement policies, and the entry of biosimilars influence stability most.
Q2: How could biosimilar entry affect prices?
Biosimilar competition typically lowers prices by 10-20% within 2-3 years of approval.
Q3: Which markets beyond the U.S. are relevant?
Europe, Canada, and Australia are key future markets; approval times and pricing strategies vary across regions.
Q4: Are there alternative therapies in development?
Yes, other investigational therapies, including biologics and peptide-based immunotherapies, are in clinical trials but lack approval as of 2023.
Q5: How might expanding indications impact the market?
Broader indications, such as younger children or other food allergies, could increase market size and justify higher pricing initially.
References
[1] Gupta, R., et al. (2018). The prevalence, severity, and distribution of food allergy in the U.S.: a population-based study. J Allergy Clin Immunol.
[2] MarketResearch.com. (2022). U.S. Pediatric Allergy Market Report.
[3] Avadel Pharmacare Inc. (2023). Public disclosures on Palforzia pricing.
[4] FDA. (2022). Food allergy therapeutics: pipeline overview.
